Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Other Operating Expenses: 2022-2025

Historic Other Operating Expenses for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $26.7 million.

  • Axsome Therapeutics' Other Operating Expenses rose 1.02% to $26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.6 million, marking a year-over-year decrease of 28.16%. This contributed to the annual value of $67.8 million for FY2024, which is 16.64% down from last year.
  • Latest data reveals that Axsome Therapeutics reported Other Operating Expenses of $26.7 million as of Q3 2025, which was up 285.06% from $6.9 million recorded in Q2 2025.
  • Axsome Therapeutics' Other Operating Expenses' 5-year high stood at $52.2 million during Q4 2023, with a 5-year trough of -$45.3 million in Q3 2022.
  • For the 3-year period, Axsome Therapeutics' Other Operating Expenses averaged around $17.0 million, with its median value being $12.2 million (2023).
  • In the last 5 years, Axsome Therapeutics' Other Operating Expenses soared by 90,170.07% in 2023 and then crashed by 55.73% in 2024.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Other Operating Expenses stood at -$57,946 in 2022, then spiked by 90,170.07% to $52.2 million in 2023, then crashed by 55.73% to $23.1 million in 2024, then grew by 1.02% to $26.7 million in 2025.
  • Its Other Operating Expenses stands at $26.7 million for Q3 2025, versus $6.9 million for Q2 2025 and $12.9 million for Q1 2025.